Open AccessSevere Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial
Jto Clinical And Research ReportsPeer ReviewedHui Zhu +52022Journals
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support